{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:47:41Z","timestamp":1783529261140,"version":"3.55.0"},"reference-count":123,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003971","name":"Islamic Development Bank","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003971","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.cca.2024.119894","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T09:07:38Z","timestamp":1721984858000},"page":"119894","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Precision medicine in lupus nephritis"],"prefix":"10.1016","volume":"562","author":[{"given":"Esra Nasraldin Khalil","family":"Sharafaldin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maw Shin","family":"Sim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Kun","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kawthar","family":"Alhussieni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasniza Zaman","family":"Huri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2024.119894_b0005","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1177\/0961203317739129","article-title":"Effect of immunosuppressive therapies on survival of systemic lupus erythematosus: a propensity score analysis of a longitudinal cohort","volume":"27","author":"Mok","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.cca.2024.119894_b0010","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1177\/0961203320926256","article-title":"Long-term outcomes of lupus nephritis treated with regimens based on cyclophosphamide and mycophenolate mofetil","volume":"29","author":"Prasad","year":"2020","journal-title":"Lupus"},{"key":"10.1016\/j.cca.2024.119894_b0015","article-title":"Incidence, prevalence, and mortality of lupus nephritis: a population-based study over four decades\u2014The Lupus Midwest Network (LUMEN)","author":"Hocaoglu","year":"2022","journal-title":"Arthritis. Rheumatol."},{"key":"10.1016\/j.cca.2024.119894_b0020","first-page":"1","author":"Alforaih","year":"2022","journal-title":"ReviewA Review of Lupus Nephritis"},{"key":"10.1016\/j.cca.2024.119894_b0025","first-page":"1","article-title":"Association of immune-related genetic and epigenetic alterations with lupus nephritis","author":"Mei","year":"2022","journal-title":"Kidney Dis."},{"key":"10.1016\/j.cca.2024.119894_b0030","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40257-016-0173-9","article-title":"Cutaneous lupus erythematosus: an update on pathogenesis, diagnosis and treatment","volume":"17","author":"Hejazi","year":"2016","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.cca.2024.119894_b0035","first-page":"313","article-title":"Systemic lupus erythematosus","volume":"18","author":"Rao","year":"2016","journal-title":"Indian J. Pract. Pediatr."},{"key":"10.1016\/j.cca.2024.119894_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102871","article-title":"Lupus nephritis : new progress in diagnosis and treatment","volume":"132","author":"Yu","year":"2022","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.cca.2024.119894_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103406","article-title":"Potential immunological and genetic markers associated with lupus nephritis: From pathogenicity to therapeutic drug target","author":"Sharafaldin","year":"2023","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.cca.2024.119894_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2020.100042","article-title":"Urinary biomarkers in lupus nephritis","volume":"3","author":"Arag\u00f3n","year":"2020","journal-title":"J. Transl. Autoimmun."},{"issue":"1\u20138","key":"10.1016\/j.cca.2024.119894_b0055","article-title":"Incidence of lupus nephritis flares after complete response in a thai population","volume":"10","author":"Sankhaanuruk","year":"2022","journal-title":"Med. Res. Arch."},{"key":"10.1016\/j.cca.2024.119894_b0060","doi-asserted-by":"crossref","first-page":"9704","DOI":"10.1038\/s41598-019-46039-5","article-title":"Associated clinical factors for serious infections in patients with systemic lupus erythematosus","volume":"9","author":"Jung","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cca.2024.119894_b0065","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1080\/1744666X.2020.1763793","article-title":"Systemic lupus erythematosus and risk of infection","volume":"16","author":"Barber","year":"2020","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.cca.2024.119894_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2018.11.001","article-title":"Systemic lupus erythematosus: diagnosis and clinical management","volume":"96","author":"Fava","year":"2019","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.cca.2024.119894_b0075","doi-asserted-by":"crossref","unstructured":"Rosenkranz AR, Tesar V. Lupus nephritis and ANCA-associated vasculitis\u00a0: towards precision medicine\u00a0? 2021:37\u201343. 10.1093\/ndt\/gfab166.","DOI":"10.1093\/ndt\/gfab166"},{"key":"10.1016\/j.cca.2024.119894_b0080","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.mjafi.2021.06.021","article-title":"Precision medicine: concept and tools","volume":"77","author":"Naithani","year":"2021","journal-title":"Med. J. Armed. Forces India"},{"key":"10.1016\/j.cca.2024.119894_b0085","doi-asserted-by":"crossref","first-page":"6533","DOI":"10.2147\/JIR.S363722","article-title":"Lupus nephritis: current perspectives and moving forward","volume":"15","author":"Lichtnekert","year":"2022","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.cca.2024.119894_b0090","unstructured":"Diering, Nishijima, Daniel; K. Simel, David L; Wisner, David H; Holmes JF. \u4e73\u9f20\u5fc3\u808c\u63d0\u53d6 HHS Public Access. Physiol Behav 2016;176:139\u201348. 10.1016\/j.trsl.2018.08.002.Precision."},{"key":"10.1016\/j.cca.2024.119894_b0095","first-page":"363","article-title":"High genetic risk score is associated with early disease onset, damage accrual and decreased survival in systemic lupus erythematosus","author":"Reid","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cca.2024.119894_b0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21082884","article-title":"Role of genetic variations in the hepatic handling of drugs","volume":"21","author":"Marin","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cca.2024.119894_b0105","doi-asserted-by":"crossref","unstructured":"Qing J, Song W, Tian L, Samuel SB, Li Y. Potential Small Molecules for Therapy of Lupus Nephritis Based on Genetic Effect and Immune Infiltration 2022;2022.","DOI":"10.1155\/2022\/2259164"},{"key":"10.1016\/j.cca.2024.119894_b0110","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1177\/0961203320930099","article-title":"Seventy years after Hench\u2019s Nobel prize: revisiting the use of glucocorticoids in systemic lupus erythematosus","volume":"29","author":"Ruiz-Irastorza","year":"2020","journal-title":"Lupus"},{"key":"10.1016\/j.cca.2024.119894_b0115","doi-asserted-by":"crossref","first-page":"165","DOI":"10.7326\/0003-4819-75-2-165","article-title":"Cyclophosphamide in lupus nephritis: a controlled trial","volume":"75","author":"Steinberg","year":"1971","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.cca.2024.119894_b0120","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.kint.2016.05.017","article-title":"A pathophysiology-based approach to the diagnosis and treatment of lupus nephritis","volume":"90","author":"Anders","year":"2016","journal-title":"Kidney Int."},{"key":"10.1016\/j.cca.2024.119894_b0125","article-title":"Recent advances in immunotherapies for lupus nephritis","author":"Kaneko","year":"2022","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.cca.2024.119894_b0130","doi-asserted-by":"crossref","DOI":"10.3390\/cells11030506","article-title":"Epigenetic alterations in immune cells of systemic lupus erythematosus and therapeutic implications","volume":"11","author":"Adams","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.cca.2024.119894_b0135","doi-asserted-by":"crossref","unstructured":"Halfon M, Tankeu AT, Ribi C. Mitochondrial Dysfunction in Systemic Lupus Erythematosus with a Focus on Lupus Nephritis 2024.","DOI":"10.3390\/ijms25116162"},{"key":"10.1016\/j.cca.2024.119894_b0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/lupus-2023-001038","article-title":"Circulating neutrophil extracellular trap remnants as a biomarker to predict outcomes in lupus nephritis","volume":"11","author":"Whittall-Garcia","year":"2024","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.cca.2024.119894_b0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2023.1253667","article-title":"NETosis: an emerging therapeutic target in renal diseases","volume":"14","author":"Juha","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cca.2024.119894_b0150","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1053\/j.ajkd.2007.10.041","article-title":"Antinucleosome antibodies as a marker of active proliferative lupus nephritis","volume":"51","author":"Bigler","year":"2008","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.cca.2024.119894_b0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm10040626","article-title":"Expanding the role of complement therapies: The case for lupus nephritis","volume":"10","author":"Li","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.cca.2024.119894_b0160","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1007\/s10067-020-05499-1","article-title":"Alternative complement pathway activation in thrombotic microangiopathy associated with lupus nephritis","volume":"40","author":"Mejia-Vilet","year":"2021","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.cca.2024.119894_b0165","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00467-010-1720-x","article-title":"Markers of childhood lupus nephritis indicating disease activity","volume":"26","author":"Edelbauer","year":"2011","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.cca.2024.119894_b0170","article-title":"Lupus nephritis","volume":"6","author":"Anders","year":"2020","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.cca.2024.119894_b0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2016.00055","article-title":"Systemic lupus erythematosus and deficiencies of early components of the complement classical pathway","volume":"7","author":"Macedo","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cca.2024.119894_b0180","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1177\/0961203314536478","article-title":"MBL2 gene variants coding for mannose-binding lectin deficiency are associated with increased risk of nephritis in Danish patients with systemic lupus erythematosus","volume":"23","author":"Tanha","year":"2014","journal-title":"Lupus"},{"key":"10.1016\/j.cca.2024.119894_b0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0224707","article-title":"Elevated interleukin-25 and its association to Th2 cytokines in systemic lupus erythematosus with lupus nephritis","volume":"14","author":"Selvaraja","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.cca.2024.119894_b0190","first-page":"2475","article-title":"Utility of serum Anti-C1q autoantibodies as a biomarker of lupus nephritis in children. egypt","volume":"88","author":"Elsayed","year":"2022","journal-title":"J. Hosp. Med."},{"key":"10.1016\/j.cca.2024.119894_b0195","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pathophys.2014.12.003","article-title":"Analysis of urinary TGF-\u03b21, MCP-1, NGAL, and IL-17 as biomarkers for lupus nephritis","volume":"22","author":"Susianti","year":"2015","journal-title":"Pathophysiology"},{"key":"10.1016\/j.cca.2024.119894_b0200","doi-asserted-by":"crossref","first-page":"i55","DOI":"10.1093\/rheumatology\/kew427","article-title":"Pathways leading to an immunological disease: systemic lupus erythematosus","volume":"56","author":"Zharkova","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cca.2024.119894_b0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2017.00405","article-title":"Interleukin-6 signaling pathway and its role in kidney disease: An update","volume":"8","author":"Su","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cca.2024.119894_b0210","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1136\/ard.62.6.556","article-title":"Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: Significant factors associated with lupus nephritis","volume":"62","author":"Alba","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cca.2024.119894_b0215","doi-asserted-by":"crossref","first-page":"150","DOI":"10.4078\/jrd.2021.28.3.150","article-title":"Clinical and genetic risk factors associated with the presence of lupus nephritis","volume":"28","author":"Shin","year":"2021","journal-title":"J. Rheum. Dis."},{"key":"10.1016\/j.cca.2024.119894_b0220","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1177\/09612033211006781","article-title":"Association of antiphospholipid antibodies with clinical activity and renal pathological activity in patients with lupus nephritis","volume":"30","author":"Zhang","year":"2021","journal-title":"Lupus"},{"key":"10.1016\/j.cca.2024.119894_b0225","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1007\/s10067-019-04917-3","article-title":"Antiphospholipid antibodies in patients with proliferative and membranous lupus nephritis","volume":"39","author":"Ding","year":"2020","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.cca.2024.119894_b0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-019-2038-0","article-title":"ALW peptide ameliorates lupus nephritis in MRL\/lpr mice","volume":"21","author":"Wang","year":"2019","journal-title":"Arthritis. Res. Ther."},{"key":"10.1016\/j.cca.2024.119894_b0235","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.autrev.2019.03.004","article-title":"Refractory lupus nephritis: When, why and how to treat","volume":"18","author":"Kronbichler","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.cca.2024.119894_b0240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/rmdopen-2020-001263","article-title":"Management of lupus nephritis: A systematic literature review informing the 2019 update of the joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations","volume":"6","author":"Kostopoulou","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.cca.2024.119894_b0245","doi-asserted-by":"crossref","unstructured":"Parodis I, Tamirou F, Houssiau FA. Treat-to-Target in Lupus Nephritis. What is the Role of the Repeat Kidney Biopsy? Arch Immunol Ther Exp (Warsz) 2022;70. 10.1007\/s00005-022-00646-9.","DOI":"10.1007\/s00005-022-00646-9"},{"key":"10.1016\/j.cca.2024.119894_b0250","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrrheum.2015.159","article-title":"What is damaging the kidney in lupus nephritis?","volume":"12","author":"Davidson","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.cca.2024.119894_b0255","first-page":"11","article-title":"Clinical characteristics of patients with lupus nephritis in a tertiary care hospital in malaysia-a cross sectional study","volume":"4","author":"Sulaiman","year":"2021","journal-title":"Asian J. Med. Heal Sci."},{"key":"10.1016\/j.cca.2024.119894_b0260","first-page":"1","article-title":"Efficacy of voclosporin in proliferative lupus nephritis with high levels of proteinuria","author":"YMenn-Josephy","year":"2023","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.cca.2024.119894_b0265","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int."},{"key":"10.1016\/j.cca.2024.119894_b0270","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 Update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cca.2024.119894_b0275","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000430458","article-title":"Lupus Nephritis in Asia: clinical features and management","volume":"1","author":"Yap","year":"2015","journal-title":"Kidney Dis."},{"key":"10.1016\/j.cca.2024.119894_b0280","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.clim.2018.08.013","article-title":"Cytokine targets in lupus nephritis: Current and future prospects","volume":"206","author":"Adamichou","year":"2019","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.cca.2024.119894_b0285","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1007\/s10067-019-04473-w","article-title":"Efficacy of mycophenolate mofetil in Japanese patients with systemic lupus erythematosus","volume":"38","author":"Kawazoe","year":"2019","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.cca.2024.119894_b0290","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/1756-185X.13254","article-title":"Chronicity index, especially glomerular sclerosis, is the most powerful predictor of renal response following immunosuppressive treatment in patients with lupus nephritis","volume":"21","author":"Park","year":"2018","journal-title":"Int. J. Rheum. Dis."},{"key":"10.1016\/j.cca.2024.119894_b0295","article-title":"ur l P re of","author":"Nasraldin","year":"2023","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.cca.2024.119894_b0300","first-page":"2611","article-title":"Involvement of TWEAK and the NF-\u03baB signaling pathway in lupus nephritis","volume":"15","author":"Sun","year":"2018","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.cca.2024.119894_b0305","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4103\/1319-2442.318522","article-title":"Urinary tumor necrosis factor-like weak inducer of apoptosis (uTWEAK) and urinary monocyte chemo-attractant protein-1 (uMCP-1): Promising biomarkers of lupus nephritis activity?","volume":"32","author":"Elsaid","year":"2021","journal-title":"Saudi J. Kidney Dis. Transplant."},{"key":"10.1016\/j.cca.2024.119894_b0310","article-title":"Autoantibodies in lupus nephritis useful in distinguishing proliferative nephritis from membranous nephritis","author":"Asanuma","year":"2022","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.cca.2024.119894_b0315","doi-asserted-by":"crossref","unstructured":"Aguirre-valencia D, R\u00edos-serna LJ, Naranjo-escobar J, Bedoya-joaqui V, Nieto-aristiz I, Navarro EP, et al. Expression of BAFF , APRIL , and cognate receptor genes in lupus nephritis and potential use as urinary biomarkers 2020;3. 10.1016\/j.jtauto.2019.100027.","DOI":"10.1016\/j.jtauto.2019.100027"},{"key":"10.1016\/j.cca.2024.119894_b0320","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/cei.12894","article-title":"Urinary B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL): potential biomarkers of active lupus nephritis","volume":"187","author":"Phatak","year":"2017","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.cca.2024.119894_b0325","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1177\/0961203320904997","article-title":"Serum and urine TNF-like weak inducer of apoptosis, monocyte chemoattractant protein-1 and neutrophil gelatinase-associated lipocalin as biomarkers of disease activity in patients with systemic lupus erythematosus","volume":"29","author":"Mirioglu","year":"2020","journal-title":"Lupus"},{"key":"10.1016\/j.cca.2024.119894_b0330","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1177\/09612033211004727","article-title":"Clinico-pathological associations of serum VCAM-1 and ICAM-1 levels in patients with lupus nephritis","volume":"30","author":"Yu","year":"2021","journal-title":"Lupus"},{"key":"10.1016\/j.cca.2024.119894_b0335","doi-asserted-by":"crossref","unstructured":"Ng CR. AB0453 ROLE OF COMBINATION AUTOANTIBODIES (ANTI-SMITH, Ro AND RNP ANTIBODIES) AND ETHNICITY IN ACCELERATED DEVELOPMENT OF LUPUS NEPHRITIS. Ann Rheum Dis 2022;81:1354.2-1354. 10.1136\/annrheumdis-2022-eular.393.","DOI":"10.1136\/annrheumdis-2022-eular.393"},{"key":"10.1016\/j.cca.2024.119894_b0340","first-page":"246","article-title":"Elevated expression of receptors for EGF, PDGF, transferrin and folate within murine and human lupus nephritis kidneys","author":"Xie","year":"2023","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.cca.2024.119894_b0345","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/acr.22502","article-title":"Epidemiology of systemic lupus erythematosus and cutaneous lupus erythematosus in a predominantly white population in the United States","volume":"67","author":"Jarukitsopa","year":"2015","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"10.1016\/j.cca.2024.119894_b0350","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1002\/art.22079","article-title":"The prevalence and incidence of biopsy-proven lupus nephritis in the UK: evidence of an ethnic gradient","volume":"54","author":"Patel","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.cca.2024.119894_b0355","first-page":"52","article-title":"A meta-analysis of clinical manifestations in asian systemic lupus erythematous: the effects of ancestry, ethnicity and gender","author":"Lee","year":"2022","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.cca.2024.119894_b0360","doi-asserted-by":"crossref","unstructured":"C.M. Lanata J. Nititham K.E. Taylor S.A. Chung G. Torgerson M.F. Seldin et al. Genetic Contributions to Lupus Nephritis in a Multi-Ethnic Cohort of Systemic Lupus Erythematous Patients 2018 1 15.","DOI":"10.1371\/journal.pone.0199003"},{"key":"10.1016\/j.cca.2024.119894_b0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2022.155975","article-title":"Cytokine Immune-relevant genes of systemic lupus erythematosus by transcriptome profiling analysis","volume":"158","author":"Lv","year":"2022","journal-title":"Cytokine"},{"key":"10.1016\/j.cca.2024.119894_b0370","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1093\/hmg\/ddaa030","article-title":"Genome-wide assessment of genetic risk for systemic lupus erythematosus and disease severity","volume":"29","author":"Chen","year":"2020","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.cca.2024.119894_b0375","doi-asserted-by":"crossref","unstructured":"Song K, Liu L, Zhang X, Chen X. Erratum: An update on genetic susceptibility in lupus nephritis (Clinical Immunology (2020) 210, (S1521661619303365), (10.1016\/j.clim.2019.108272)). Clin Immunol 2020;215:108389. 10.1016\/j.clim.2020.108389.","DOI":"10.1016\/j.clim.2020.108389"},{"key":"10.1016\/j.cca.2024.119894_b0380","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1681\/ASN.2013050446","article-title":"Lupus nephritis susceptibility loci in women with systemic lupus erythematosus","volume":"25","author":"Chung","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.cca.2024.119894_b0385","volume":"12","author":"Almaani","year":"2017","journal-title":"Update on Lupus Nephritis."},{"key":"10.1016\/j.cca.2024.119894_b0390","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmed.2020.598665","article-title":"HLA-DRB1*04 as a risk allele to systemic lupus erythematosus and lupus nephritis in the malay population of malaysia","volume":"7","author":"Selvaraja","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.cca.2024.119894_b0395","first-page":"570","article-title":"Association of TNFAIP3 gene polymorphism (rs5029939) with susceptibility and clinical phenotype of systemic lupus erythematosus","volume":"36","author":"Gaballah","year":"2021","journal-title":"Arch. Rheumatol."},{"key":"10.1016\/j.cca.2024.119894_b0400","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1080\/03009742.2016.1194458","article-title":"Association of the IKZF1 5\u02b9 UTR variant rs1456896 with lupus nephritis in a northern Han Chinese population","volume":"46","author":"Zhang","year":"2017","journal-title":"Scand. J. Rheumatol."},{"key":"10.1016\/j.cca.2024.119894_b0405","first-page":"939","article-title":"Fc-gamma receptor polymorphisms differentially influence susceptibility to systemic lupus erythematosus and lupus nephritis","volume":"55","author":"Tsang-A-Sjoe","year":"2016","journal-title":"Rheumatol (united Kingdom)"},{"key":"10.1016\/j.cca.2024.119894_b0410","doi-asserted-by":"crossref","first-page":"22543","DOI":"10.1002\/jcp.28818","article-title":"Association between TL1A gene polymorphisms and systemic lupus erythematosus in a Chinese Han population","volume":"234","author":"Xu","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.cca.2024.119894_b0415","first-page":"4497","article-title":"Low copy number of FCGR3B is associated with lupus nephritis in a Chinese population","volume":"14","author":"Zheng","year":"2017","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.cca.2024.119894_b0420","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/03009742.2018.1488273","article-title":"Peptidylarginine deiminase-4 gene polymorphisms are associated with systemic lupus erythematosus and lupus nephritis","volume":"48","author":"Massarenti","year":"2019","journal-title":"Scand. J. Rheumatol."},{"key":"10.1016\/j.cca.2024.119894_b0425","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/mgg3.1648","article-title":"Association of the STAT4, CDKN1A, and IRF5 variants with risk of lupus nephritis and renal biopsy classification in patients in Vietnam","volume":"9","author":"Nghiem","year":"2021","journal-title":"Mol. Genet. Genomic Med."},{"key":"10.1016\/j.cca.2024.119894_b0430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12865-022-00520-5","article-title":"GBP2 acts as a member of the interferon signalling pathway in lupus nephritis","volume":"23","author":"Zhang","year":"2022","journal-title":"BMC Immunol."},{"key":"10.1016\/j.cca.2024.119894_b0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107598","article-title":"International Immunopharmacology MCP-1: Function, regulation, and involvement in disease","volume":"101","author":"Singh","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.cca.2024.119894_b0440","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s41435-021-00142-8","article-title":"Variants in BANK1 are associated with lupus nephritis of European ancestry","volume":"22","author":"Bolin","year":"2021","journal-title":"Genes Immun."},{"key":"10.1016\/j.cca.2024.119894_b0445","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2019.02026","article-title":"Transcriptomic and epigenetic alterations in dendritic cells correspond with chronic kidney disease in lupus nephritis","volume":"10","author":"Wardowska","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cca.2024.119894_b0450","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1093\/ndt\/gfy284","article-title":"Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis","volume":"35","author":"Yap","year":"2020","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.cca.2024.119894_b0455","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s10067-020-05276-0","article-title":"Influence of glutathione S transferase A1 gene polymorphism (-69C > T, rs3957356) on intravenous cyclophosphamide efficacy and side effects: a case-control study in Egyptian patients with lupus nephritis","volume":"40","author":"Attia","year":"2021","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.cca.2024.119894_b0460","first-page":"1","article-title":"Association between genetic polymorphisms of metabolic enzymes and azathioprine-induced myelosuppression in 1,419 Chinese Patients: A retrospective study","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cca.2024.119894_b0465","first-page":"713","article-title":"Influence of SLCO1B1 521T>C, UGT2B7 802C>T and IMPDH1 \u2212106G>A Genetic polymorphisms on mycophenolic acid levels and adverse reactions in Chinese autoimmune disease patients","volume":"14","author":"Shu","year":"2021","journal-title":"Pharmgenomics Pers. Med."},{"key":"10.1016\/j.cca.2024.119894_b0470","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.2217\/pgs-2017-0069","article-title":"Epistatic interactions among CYP2C19\u22172, CYP3A4 and GSTP1 on the cyclophosphamide therapy in lupus nephritis patients","volume":"18","author":"Kumaraswami","year":"2017","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.cca.2024.119894_b0475","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1016\/j.transproceed.2022.07.009","article-title":"Frequencies and association of CYP3A5 polymorphism with tacrolimus concentration among renal transplant recipients in Vietnam","volume":"54","author":"Xuan","year":"2022","journal-title":"Transpl. Proc."},{"key":"10.1016\/j.cca.2024.119894_b0480","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2478\/s11756-020-00577-w","article-title":"Relationship of MDR1 gene polymorphism and P-glycoprotein expression in Chinese refractory lupus nephritis","volume":"76","author":"Zhou","year":"2021","journal-title":"Biologia (Bratisl)"},{"key":"10.1016\/j.cca.2024.119894_b0485","first-page":"1463","article-title":"Genetic polymorphisms affecting tacrolimus metabolism and the relationship to post-transplant outcomes in kidney transplant recipients","volume":"14","author":"Cheng","year":"2021","journal-title":"Pharmgenomics Pers. Med."},{"key":"10.1016\/j.cca.2024.119894_b0490","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s12016-021-08898-7","article-title":"The therapeutic strategies for SLE by Targeting Anti-dsDNA Antibodies","volume":"63","author":"Wang","year":"2022","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.cca.2024.119894_b0495","first-page":"1","article-title":"Anti-double stranded DNA antibodies: Origin, pathogenicity, and targeted therapies","volume":"10","author":"Wang","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cca.2024.119894_b0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106451","article-title":"International immunopharmacology alterations in peripheral blood B cells in systemic lupus erythematosus patients with renal insufficiency","volume":"83","author":"Wardowska","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.cca.2024.119894_b0505","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.cca.2024.119894_b0510","article-title":"The safety and efficacy of rituximab and belimumab in systemic lupus erythematosus: A systematic review","volume":"15","author":"Abid","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.cca.2024.119894_b0515","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2024.119894_b0520","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2147\/RRU.S385836","article-title":"Promising experimental treatments for lupus nephritis: key talking points and potential opportunities","volume":"15","author":"Neves","year":"2023","journal-title":"Res. Reports Urol."},{"key":"10.1016\/j.cca.2024.119894_b0525","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1080\/17512433.2022.2092470","article-title":"Voclosporin: a novel calcineurin inhibitor for the treatment of lupus nephritis","volume":"15","author":"van Gelder","year":"2022","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.cca.2024.119894_b0530","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/ndt\/gfy267","article-title":"B-cell therapy in lupus nephritis: an overview","volume":"34","author":"Almaani","year":"2019","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.cca.2024.119894_b0535","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/art.42657","article-title":"Safety and efficacy of long-term voclosporin treatment for lupus nephritis in the phase 3 AURORA 2 clinical trial","volume":"76","author":"Saxena","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.cca.2024.119894_b0540","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1007\/s00296-023-05389-0","article-title":"Experience with abatacept in refractory lupus nephritis","volume":"43","author":"Calatayud","year":"2023","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.cca.2024.119894_b0545","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1093\/ndt\/gfac296","article-title":"The role of complement in glomerulonephritis - are novel therapies ready for prime time?","volume":"38","author":"Cheung","year":"2023","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.cca.2024.119894_b0550","article-title":"Complement inhibitors for kidney disease","author":"Wooden","year":"20233829","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.cca.2024.119894_b0555","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.2147\/DDDT.S170969","article-title":"Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date","volume":"13","author":"Felten","year":"2019","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.cca.2024.119894_b0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103188","article-title":"Autoimmunity Reviews Do biological agents improve health-related quality of life in patients with systemic lupus erythematosus ? Results from a systematic search of the literature","volume":"21","author":"Gomez","year":"2022","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.cca.2024.119894_b0565","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-23361-z","article-title":"Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus","volume":"12","author":"Hasni","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cca.2024.119894_b0570","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.nefro.2016.05.020","article-title":"Role of TWEAK\/Fn14 signalling pathway in lupus nephritis and other clinical settings","volume":"37","author":"Gonz\u00e1lez-S\u00e1nchez","year":"2017","journal-title":"Nefrologia"},{"key":"10.1016\/j.cca.2024.119894_b0575","first-page":"5","article-title":"TWEAK\u2013Fn14 as a common pathway in the heart and the kidneys in cardiorenal syndrome","volume":"254","author":"Poveda","year":"2021","journal-title":"J. Pathol."},{"key":"10.1016\/j.cca.2024.119894_b0580","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3899\/jrheum.090194","article-title":"Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Fas lpr mice: The IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus","volume":"37","author":"Cash","year":"2010","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.cca.2024.119894_b0585","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1002\/art.39722","article-title":"A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of treatment with sirukumab (CNTO 136) in patients with active lupus nephritis","volume":"68","author":"Rovin","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.cca.2024.119894_b0590","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/S0140-6736(18)32167-6","article-title":"Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study","volume":"392","author":"van Vollenhoven","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.cca.2024.119894_b0595","first-page":"10","article-title":"Current evidence for IL-17\/23 blockade for the treatment of lupus nephritis","volume":"13","author":"Santacruz","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.cca.2024.119894_b0600","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1136\/ard-2022-222858","article-title":"Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus","author":"Van Vollenhoven","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cca.2024.119894_b0605","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175823","article-title":"Luteolin attenuates lupus nephritis by regulating macrophage oxidative stress via HIF-1\u03b1 pathway","volume":"953","author":"Ding","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.cca.2024.119894_b0610","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1053\/j.ajkd.2018.02.347","article-title":"CRISPR Gene Editing in the Kidney","volume":"71","author":"Cruz","year":"2018","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.cca.2024.119894_b0615","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1093\/ndt\/gfy009","article-title":"Targeting epigenetic DNA and histone modifications to treat kidney disease","volume":"33","author":"Fontecha-Barriuso","year":"2018","journal-title":"Nephrol. Dial. Transplant."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898124021478?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898124021478?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,24]],"date-time":"2024-11-24T21:41:58Z","timestamp":1732484518000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898124021478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":123,"alternative-id":["S0009898124021478"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2024.119894","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision medicine in lupus nephritis","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2024.119894","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119894"}}